Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division

Autor: Jennifer A. Chan, Heather A. Jacene, Christopher Sakellis, Lauren Gilbert, Annick D. Van den Abbeele, Matthew H. Kulke, Yuji Kuzuhara, Eric Andersen, Amanda Abbott, Kelly Boyle

Publikováno v: Journal of Nuclear Medicine Technology. 46:237-244

177Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Radionuclide therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0006a13f6bac51a84c09cc97c040915c
https://doi.org/10.2967/jnmt.118.209148

Guidance on ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.

Autor: Abbott, Amanda, Sakellis, Christopher G., Andersen, Eric, Yuji Kuzuhara, Gilbert, Lauren, Boyle, Kelly, Kulke, Matthew H., Chan, Jennifer A., Jacene, Heather A., Abbeele, Annick D. Van den

Publikováno v: Journal of Nuclear Medicine Technology; Sep2018, Vol. 46 Issue 3, p237-244, 8p, 3 Color Photographs, 2 Diagrams, 5 Charts